Cranial irradiation is an essential part of treatment for patients with a pediatric brain tumor. Unfortunately, radiation to young children causes a debilitating cognitive decline, such as learning and memory deficits, which significantly compromises the quality of life of young cancer survivors. Although the specific etiology for the learning and memory deficits has not been established, previous studies suggest that decreased neurogenesis, increased neuroinflammation and impairments of hippocampal synaptic plasticity may contribute to impaired cognitive function. Noradrenaline (NA) is a neurotransmitter produced by the Locus Coeruleus, known to have important neuroprotective and anti-inflammatory effects and to stimulate neurogenesis, synaptic plasticity, and hippocampus-based memory formation. Recently, preliminary findings have shown that NA agonists have a significant neuroprotective and anti-inflammatory effect in the hippocampus after irradiation, which highlights that the NA-system can be a novel target to mitigate radiation-induced hippocampal injury. For this reason, I will investigate whether pharmacological stimulation of the NA-system will improve radiation-induced deficits by focusing on different levels ranging from molecular to behavior. Eventually, the knowledge acquired in this study can be used to develop novel therapeutic approaches against radiation-induced neurocognitive dysfunction in order to improve the quality of life of young cancer survivors.